Tags

Type your tag names separated by a space and hit enter

[Significance of detection of K-ras gene mutations and CA19-9 in serum for diagnosis of pancreatic carcinoma].
Ai Zheng. 2003 Mar; 22(3):295-7.AZ

Abstract

BACKGROUND & OBJECTIVE

The early diagnosis of pancreatic carcinoma is difficult. The serum tumor markers such as CA19-9 have a relatively high sensitivity but with low specificity. The oncogene K-ras is frequently mutated in pancreatic carcinoma and with high specificity. The aim of this study was to assess the feasibility of detection of K-ras mutation combined with serum content of CA19-9 as an approach for diagnosis of pancreatic carcinoma.

METHODS

Serum DNA was extracted from 39 patients with pancreatic carcinoma. Mutation enriched polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to determine codon 12 mutations of K-ras. Serum content of CA19-9 was determined by radioimmunoassay. In addition, the sera from 17 patients with other pancreatic diseases and 21 healthy individuals were also analyzed as control.

RESULTS

K-ras gene mutations at codon 12 were detected in the sera of 71.79%(28/39) patients with pancreatic carcinoma and 11.76%(2/17) of patients with benign pancreatic tumors. The positive rates of CA19-9 were 71.79% and 41.18%, respectively. Parallel combined test increased the diagnostic sensitivity to 94.87%; and serial combined test increased the diagnostic specificity to 94.12%. Negative results of K-ras gene and CA19-9 were obtained in all sera from healthy controls.

CONCLUSION

Combined detection of K-ras mutation and CA19-9 could increase the sensitivity and specificity in diagnosing pancreatic carcinoma, and would seem to be merited in clinic.

Authors+Show Affiliations

Institute of Digestive Surgery, Ruijin Hospital, Shanghai Second Medical University, Shanghai, 200025, P.R. China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

chi

PubMed ID

12654190

Citation

Zhang, Yi, et al. "[Significance of Detection of K-ras Gene Mutations and CA19-9 in Serum for Diagnosis of Pancreatic Carcinoma]." Ai Zheng = Aizheng = Chinese Journal of Cancer, vol. 22, no. 3, 2003, pp. 295-7.
Zhang Y, Ji SR, Feng DX, et al. [Significance of detection of K-ras gene mutations and CA19-9 in serum for diagnosis of pancreatic carcinoma]. Ai Zheng. 2003;22(3):295-7.
Zhang, Y., Ji, S. R., Feng, D. X., Ji, J., & Han, T. Q. (2003). [Significance of detection of K-ras gene mutations and CA19-9 in serum for diagnosis of pancreatic carcinoma]. Ai Zheng = Aizheng = Chinese Journal of Cancer, 22(3), 295-7.
Zhang Y, et al. [Significance of Detection of K-ras Gene Mutations and CA19-9 in Serum for Diagnosis of Pancreatic Carcinoma]. Ai Zheng. 2003;22(3):295-7. PubMed PMID: 12654190.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Significance of detection of K-ras gene mutations and CA19-9 in serum for diagnosis of pancreatic carcinoma]. AU - Zhang,Yi, AU - Ji,Shu-Rong, AU - Feng,Dian-Xu, AU - Ji,Jun, AU - Han,Tian-Quan, PY - 2003/3/26/pubmed PY - 2003/9/13/medline PY - 2003/3/26/entrez SP - 295 EP - 7 JF - Ai zheng = Aizheng = Chinese journal of cancer JO - Ai Zheng VL - 22 IS - 3 N2 - BACKGROUND & OBJECTIVE: The early diagnosis of pancreatic carcinoma is difficult. The serum tumor markers such as CA19-9 have a relatively high sensitivity but with low specificity. The oncogene K-ras is frequently mutated in pancreatic carcinoma and with high specificity. The aim of this study was to assess the feasibility of detection of K-ras mutation combined with serum content of CA19-9 as an approach for diagnosis of pancreatic carcinoma. METHODS: Serum DNA was extracted from 39 patients with pancreatic carcinoma. Mutation enriched polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to determine codon 12 mutations of K-ras. Serum content of CA19-9 was determined by radioimmunoassay. In addition, the sera from 17 patients with other pancreatic diseases and 21 healthy individuals were also analyzed as control. RESULTS: K-ras gene mutations at codon 12 were detected in the sera of 71.79%(28/39) patients with pancreatic carcinoma and 11.76%(2/17) of patients with benign pancreatic tumors. The positive rates of CA19-9 were 71.79% and 41.18%, respectively. Parallel combined test increased the diagnostic sensitivity to 94.87%; and serial combined test increased the diagnostic specificity to 94.12%. Negative results of K-ras gene and CA19-9 were obtained in all sera from healthy controls. CONCLUSION: Combined detection of K-ras mutation and CA19-9 could increase the sensitivity and specificity in diagnosing pancreatic carcinoma, and would seem to be merited in clinic. UR - https://www.unboundmedicine.com/medline/citation/12654190/[Significance_of_detection_of_K_ras_gene_mutations_and_CA19_9_in_serum_for_diagnosis_of_pancreatic_carcinoma]_ L2 - https://medlineplus.gov/pancreaticcancer.html DB - PRIME DP - Unbound Medicine ER -